Forodesine

• CAT Number: I002612
• CAS Number: 209799-67-7
• Molecular Formula: C11H14N4O4
• Molecular Weight: 266.25
• Purity: ≥95%
• Target: PNP inhibitor
• Solubility: 10 mM in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: 7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
• InChI: InChI=1S/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1
• InChIKey: IWKXDMQDITUYRK-KUBHLMPHSA-N
• SMILES: C1=C(C2=C(N1)C(=O)NC=N2)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O

Forodesine（Cat No.:I002612）is a potent purine nucleoside phosphorylase (PNP) inhibitor used primarily in the treatment of hematologic malignancies such as T-cell acute lymphoblastic leukemia (T-ALL) and chronic lymphocytic leukemia (CLL). By inhibiting PNP, Forodesine disrupts the purine salvage pathway, leading to the accumulation of toxic deoxyguanosine triphosphate (dGTP) in T-cells, which induces apoptosis. This targeted mechanism selectively affects malignant T-cells while sparing normal cells, making Forodesine a promising therapeutic agent. Its efficacy and specificity offer hope for improved outcomes in patients with refractory or relapsed T-cell cancers.